The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology.
10.3346/jkms.2016.31.11.1735
- Author:
Soyeon LEE
1
;
Hyo Gyoung KANG
;
Jin Eun CHOI
;
Jang Hyuck LEE
;
Hyo Jung KANG
;
Sun Ah BAEK
;
Eungbae LEE
;
Yangki SEOK
;
Won Kee LEE
;
Shin Yup LEE
;
Seung Soo YOO
;
Jaehee LEE
;
Seung Ick CHA
;
Chang Ho KIM
;
Sukki CHO
;
Jae Yong PARK
Author Information
1. Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. jaeyong@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Non-Small Cell Lung Cancer;
Survival;
Angiogenesis;
Polymorphisms;
Histology
- MeSH:
Adenocarcinoma;
Carcinoma, Non-Small-Cell Lung*;
Carcinoma, Squamous Cell;
Disease-Free Survival;
Genotype;
Humans;
Lung Neoplasms;
Polymorphism, Single Nucleotide;
Population Characteristics;
Prognosis*;
Vascular Endothelial Growth Factor A*
- From:Journal of Korean Medical Science
2016;31(11):1735-1741
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vascular endothelial growth factor (VEGF) contributes to tumor angiogenesis. The role of VEGF single nucleotide polymorphisms (SNPs) in lung cancer susceptibility and its prognosis remains inconclusive and controversial. This study was performed to investigate whether VEGF polymorphisms affect survival outcomes of patients with early stage non-small cell lung cancer (NSCLC) after surgery. Three potentially functional VEGF SNPs (rs833061T>C, rs2010963G>C, and rs3025039C>T) were genotyped. A total of 782 NSCLC patients who were treated with surgical resection were enrolled. The association of the SNPs with overall survival (OS) and disease free survival (DFS) was analyzed. In overall population, none of the three polymorphisms were significantly associated with OS or DFS. However, when the patients were stratified by tumor histology, squamous cell carcinoma (SCC) and adenocarcinoma (AC) had significantly different OS (Adjusted hazard ratio [aHR] = 0.76, 95% CI = 0.56–1.03 in SCC; aHR = 1.33, 95% CI = 0.98–1.82 in AC; P for heterogeneity = 0.01) and DFS (aHR = 0.75, 95% CI = 0.58–0.97 in SCC; aHR = 1.26, 95% CI = 1.00–1.60 in AC; P for heterogeneity = 0.004) according to the rs833061T>C genotypes. Our results suggest that the prognostic role of VEGF rs833061T>C may differ depending on tumor histology.
